Department of Radiotherapy, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Int J Dermatol. 2022 Aug;61(8):911-915. doi: 10.1111/ijd.16008. Epub 2021 Nov 24.
The optimal definitive radiotherapy (RT) scheme in cutaneous squamous cell carcinoma (cSCC) remains controversial, especially in elderly patients.
Data of elderly patients with cSCC lesion(s) treated with weekly hypofractionated RT (8 Gy per week per 7-8 weeks) were analyzed.
Eighteen patients (median age 89 years) with 23 cSCC lesions have been identified including nine males (50%) and nine females (50%). The most common tumor localization was the head and neck region (n = 21; 91.3%), and the majority of lesions (n = 15; 65.2%) was stage ≥ III. At diagnosis, pain and bleeding were ascribed in 13 (56.5%) and eight (34.8%) cSCC, respectively. Compliance with weekly hypofractionated RT was excellent. The overall response rate at 12 weeks after treatment was 95.7%. Bleeding and pain relief were achieved in all cases. Severe toxicity was not recorded. The 1-year overall survival was 66.0%. The 1-year progression-free survival was 58.7%.
Weekly hypofractionated RT provides a safe, efficient, and cost-effective treatment in elderly cSCC patients with minimal side effects.
皮肤鳞状细胞癌（cSCC）的最佳根治性放疗（RT）方案仍存在争议，尤其是在老年患者中。
分析了每周接受低分割 RT（每周 8Gy，共 7-8 周）治疗的老年 cSCC 患者的数据。
共确定了 18 例（中位年龄 89 岁）患有 23 处 cSCC 病变的老年患者，包括 9 名男性（50%）和 9 名女性（50%）。最常见的肿瘤部位是头颈部（n=21；91.3%），大多数病变（n=15；65.2%）处于≥III 期。诊断时，13 例（56.5%）和 8 例（34.8%）cSCC 分别出现疼痛和出血。每周接受低分割 RT 的依从性非常好。治疗后 12 周的总缓解率为 95.7%。所有病例均实现了出血和疼痛缓解。未记录到严重毒性。1 年总生存率为 66.0%。1 年无进展生存率为 58.7%。
每周低分割 RT 为老年 cSCC 患者提供了一种安全、有效且具有成本效益的治疗方法，副作用极小。
